We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Bethlehem Pharmaceuticals Plc, a privately owned drug manufacturer, has requested close to nine million Br in loans from the Development Bank of Ethiopia (DBE), after it survived a foreclosure move in September 2006 by the same Bank.
The South African government's controversial medicine-pricing regulations, which were to have been introduced finally on Jan. 1 after a long-running legal battle between pharmacists and the health department, have once again been put on hold, according to Business Day Johannesburg.
Pfizer announced Dec. 20 it is launching an online site where the progress of compounds in its research and development pipeline will be made available to investors, plus the scientific and medical communities, and regularly updated.
ImmunoGen Dec. 26 announced that sanofi-aventis has entered into an option agreement that enables it to gain expanded access to the company's Tumor-Activated Prodrug (TAP) technology.
Bristol-Myers Squibb (BMS) and Otsuka Pharmaceutical today announced Otsuka has been granted exclusive rights in Japan to develop and commercialize the investigational compound saxagliptin, being studied for the treatment of Type 2 diabetes.
In observance of the holiday season, Daily International Pharma
Alert will not be published Friday, Dec. 22, Monday, Dec. 25, or Tuesday, Dec. 26. The next issue will be published Wednesday, Dec. 27.
GlaxoSmithKline (GSK) has announced it will acquire U.S. biopharmaceutical firm Praecis Pharmaceuticals in a definitive agreement under which GSK will acquire all outstanding shares of Praecis' common stock for a cash purchase price of $5.00 per share, for a total of approximately $54.8 million.
Sanofi pasteur has completed production of more than 170 million doses of influenza vaccine, making the French drugmaker the largest contributor to this year's global supply, the company said.